Our Work

Foundational Projects

As we establish this network, we are guided by two main objectives:

Mucinous Ovarian Carcinoma (MOC)

Mucinous ovarian carcinoma (MOC) accounts for about 3-5% of all ovarian cancers. MOC poses unique clinical challenges due to its distinct biological behaviour, diagnostic complexity, and treatment resistance. MOC often presents at an early stage in younger women. There is limited data regarding optimal treatment strategies and resulting patient outcomes. Therefore, a systematic evaluation of treatment patterns, outcomes, and prognostic factors is critical.

Objective 1: Patterns of care in patients with MOC

Goal: To evaluate care patterns, how they are influenced by individual characteristics, and the outcomes associated with each treatment approach in MOC patients

Objective 2: Comparative Outcomes of First-Line Chemotherapy Regimens in Advanced/High-Risk Mucinous Ovarian Cancer

Goal: To compare the outcomes between GI/non-ovarian-based regimens and standard ovarian-based chemotherapy in advanced/high-risk MOC.

Objective 3: Efficacy of First- and Second-Line Chemotherapy Regimens in Recurrent MOC

Goal: To compare outcomes of GI/non-ovarian-based regimens to standard ovarian-based chemotherapy in recurrent MOC

Objective 4: Treatment Outcomes with Second Recurrence of MOC: An Exploratory Analysis

Goal: To explore treatment outcomes in women with recurrent MOC, focusing on the effectiveness of different therapies, including targeted therapy.

Low-Grade Serous Ovarian Cancer (LGSOC)

Low-grade serous ovarian cancer (LGSOC) accounts for about 5% of ovarian cancers. Unlike the more common high-grade serous ovarian cancers, LGSOC has a lower proliferative rate, a slower growth pattern, and generally presents at a younger age. LGSOC faces unique challenges due to its inherent resistance to standard chemotherapy and tendency for recurrence. The search for personalized and effective treatment strategies is needed.

Objective 1: Outcomes of Treatment in Newly Diagnosed Patients

Goal: To evaluate the clinical outcomes of treatment regimens in newly diagnosed LGSOC patients: chemotherapy alone, chemotherapy combined with bevacizumab, hormonal maintenance therapy, and hormonal monotherapy.

Objective 2: Outcomes of Treatment Strategies in Patients with Relapsed LGSOC

Goal: To review treatment outcomes and patterns with relapsed LGSOC, providing insights into the effectiveness of various therapies based on prior treatment history.

Objective 3: Evaluating Fertility-Sparing Surgery Outcomes in Young Patients with LGSOC

Goal: To facilitate the evaluation of fertility-sparing surgery in young patients with LGSC, focusing on the effectiveness of such interventions in preserving fertility and achieving successful pregnancies.

Presentations & Webinars

ROCCA Without Borders: Federated Analytics for Rare Ovarian Cancer Research

September 25, 2026

Dr. Aline Talhouk, ROCCA’s Coordinating Center Lead, presented an overview of federated analytics for rare ovarian cancers as part of the Gynecologic Cancer Initiative (GCI) Research Rounds.

News & Events

OCRA News: OCRA-Funded ROCCA Platform Launches to Accelerate Rare Ovarian Cancer Research

May 18, 2026

OCRA’s article on Medium: Embracing AI’s Promise in Ovarian Cancer Research: A Journey of Collaboration and Hope

February 1, 2024

Publications

TBD